Biocorp

Biocorp

Lyon, France· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $75M

Overview

Biocorp is a privately-held, integrated developer and manufacturer of connected drug delivery devices and digital health solutions. The company leverages a unique heritage in industrial plastics processing (plasturgy) combined with advanced digital innovation to create customized, connected medical devices. It controls the entire value chain from R&D to final packaging, employing over 100 people across two sites in France. Biocorp operates in a high-growth segment, aiming to enhance treatment adherence and data collection for injectable therapies.

DiabetesGrowth DisordersChronic Diseases

Technology Platform

Integrated platform combining precision plastics engineering for drug delivery devices (pens, syringes) with digital connectivity (sensors, Bluetooth, software apps, cloud data) to create smart, connected medical devices for adherence monitoring and data collection.

Funding History

6
Total raised:$75M
Series B$25M
Series B$25M
Series A$10M
Series A$10M

Opportunities

The global shift towards biologics and injectable therapies creates a large addressable market for connected delivery devices.
Increasing pressure to prove drug efficacy and value in real-world settings drives pharmaceutical company demand for adherence and outcomes data, which Biocorp's platform can provide.

Risk Factors

Revenue is dependent on a small number of large pharmaceutical partners with long sales and integration cycles.
The company faces intense competition from both established medical device giants and agile digital health startups.
Evolving regulatory landscapes for data privacy and software as a medical device pose ongoing compliance challenges.

Competitive Landscape

Biocorp competes in the connected drug delivery space against large device OEMs (e.g., Ypsomed, BD, Embecta), digital health startups, and tech companies moving into healthcare. Its differentiation lies in its hybrid model of deep manufacturing expertise combined with digital innovation, and its flexible 'add-on' Mallya system that can retrofit existing pens.